Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Regeneron's Libtayo Gains FDA Approval for Expanded Use in Skin Cancer Treatment

Regeneron's Libtayo Gains FDA Approval for Expanded Use in Skin Cancer Treatment

Regeneron Pharmaceuticals has received a significant boost as the U.S. Food and Drug Administration (FDA) approved an expanded use for its cancer immunotherapy drug, Libtayo. The latest approval allows for the treatment of a wider group of patients with cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

NoahAI News10/10/2025
Highmark Health Appoints Karen Hanlon as President, Strengthening Leadership Amid Industry Challenges

Highmark Health Appoints Karen Hanlon as President, Strengthening Leadership Amid Industry Challenges

Highmark Health, the Pittsburgh-based healthcare company, has named Karen Hanlon as its new president, effective immediately. This strategic move comes as the organization navigates through a period of growth and tackles industry-wide challenges, particularly in utilization management and cost containment.

NoahAI News10/10/2025
Digital Health Funding Surges in 2025, Driven by Mega-Deals and AI Innovation

Digital Health Funding Surges in 2025, Driven by Mega-Deals and AI Innovation

Digital health funding in 2025 is outpacing last year's figures, with investment reaching $9.9 billion through the third quarter, according to a recent report by Rock Health. This surge in funding, driven by larger deal sizes and an increase in mega-rounds, signals a shift in the digital health landscape as investors focus on AI-powered solutions and workflow optimization tools.

NoahAI News10/10/2025
Regeneron's Libtayo Secures FDA Approval for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

Regeneron's Libtayo Secures FDA Approval for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals has achieved a significant milestone as its cancer immunotherapy drug Libtayo (cemiplimab) received FDA approval for the adjuvant treatment of patients with cutaneous squamous cell carcinoma (CSCC) who are at high risk of recurrence following surgery and radiation. This latest development marks Libtayo as the first immunotherapy to receive such an indication, potentially changing the treatment landscape for this common form of skin cancer.

NoahAI News10/10/2025
Medtronic Advances in Robotic Surgery with Hugo System

Medtronic Advances in Robotic Surgery with Hugo System

Medtronic, a leading medical technology company, is making significant strides in the robotic surgery market with its Hugo robotic-assisted surgery (RAS) system. The company has initiated a new clinical study for gynecological procedures, marking another step towards challenging Intuitive Surgical's dominance in the U.S. market.

NoahAI News10/10/2025
Expedition Therapeutics Secures $165M Series A for COPD Drug Development

Expedition Therapeutics Secures $165M Series A for COPD Drug Development

Expedition Therapeutics, a Bay Area biotech company, has successfully closed a $165 million series A funding round to advance its chronic obstructive pulmonary disease (COPD) treatment program. The financing, led by Sofinnova Investments and Novo Holdings, will primarily support the phase 2 development of EXPD-101, a DPP1 inhibitor aimed at addressing the unmet needs of COPD patients.

NoahAI News10/10/2025
Ono Pharmaceutical's EP4 Antagonist Shows Promise in Phase 2 Gastric Cancer Trial

Ono Pharmaceutical's EP4 Antagonist Shows Promise in Phase 2 Gastric Cancer Trial

Ono Pharmaceutical has announced positive results from a phase 2 trial of its EP4 antagonist, ONO-4578, in combination with Bristol Myers Squibb's (BMS) Opdivo and chemotherapy for patients with HER2-negative unresectable advanced or recurrent gastric cancer or gastroesophageal junction cancer.

NoahAI News10/10/2025
Thermo Fisher Launches New Diagnostic Test to Assess Lung Transplant Rejection Risk

Thermo Fisher Launches New Diagnostic Test to Assess Lung Transplant Rejection Risk

Thermo Fisher Scientific has introduced a groundbreaking diagnostic tool aimed at improving the detection and management of lung transplant rejection. The new test, called the Molecular Microscope Diagnostic System for Lung (MMDx Lung), utilizes advanced machine learning techniques to analyze gene expression data from lung biopsies, providing physicians with crucial insights into the likelihood of transplant rejection.

NoahAI News10/10/2025
Lupin Invests $250M in New Florida Respiratory Drug Plant, Boosting US Manufacturing

Lupin Invests $250M in New Florida Respiratory Drug Plant, Boosting US Manufacturing

Indian pharmaceutical giant Lupin has announced plans to invest $250 million in a new respiratory drug manufacturing facility in Coral Springs, Florida. The move marks a significant expansion of the company's U.S. operations and aligns with the broader trend of pharmaceutical firms increasing domestic production capabilities.

NoahAI News10/10/2025
Foundation Health Secures $20M to Revolutionize Pharmacy Operations with AI

Foundation Health Secures $20M to Revolutionize Pharmacy Operations with AI

Foundation Health, a startup founded by Truepill co-founder Umar Afridi, has raised $20 million in a Series A funding round to bring artificial intelligence to pharmacy operations. The company aims to provide an AI-powered infrastructure spanning pharmacy operations, care coordination, and direct-to-patient delivery.

NoahAI News10/10/2025
Boehringer Ingelheim Strengthens U.S. Presence with Key Approvals and New Leadership

Boehringer Ingelheim Strengthens U.S. Presence with Key Approvals and New Leadership

Boehringer Ingelheim, the German pharmaceutical giant, is making significant strides in the U.S. market with recent regulatory successes and a renewed focus on commercialization. The company's efforts are spearheaded by Brian Hilberdink, who joined as president of U.S. human pharma in February, bringing fresh perspective to the company's American operations.

NoahAI News10/10/2025
Ex-Moderna Leaders Launch $325M Venture Capital Fund for Platform Biotechs

Ex-Moderna Leaders Launch $325M Venture Capital Fund for Platform Biotechs

Ascenta, a new biotech venture capital firm founded by former Moderna executives, has closed its inaugural fund at $325 million. The Florida-based company, led by Evan Rachlin, M.D., and Lorence Kim, M.D., aims to support platform biotechs in early clinical stages, focusing on companies with multiple-medicine platforms that balance risk through diversified pipelines.

NoahAI News10/10/2025
«1...454647...67»